Q3 2027
Next results · Q3 2027Projected
Feb 5, before the open
Fri, Feb 5, 2027in 80 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q3 2027 · Ends about Dec 31, 2026
- 10-Q window
- Feb 3 – 12
Read against Q3 2026
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- —
- Net income
- -$110.64M
- Net income, change from a year earlier: Q2 2027 n/m, Q1 2027 n/m, Q4 2026 n/m, Q3 2026 n/m
- EPS
- -$0.61
- EPS, change from a year earlier: Q2 2027 n/m, Q1 2027 n/m, Q3 2026 n/m, Q2 2026 n/m
Results day
Typical moveA typical move of 6.5% either way
Up after 6 of 12, down after 6.
The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: +35.3% after Q4 2026.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Varies
- Session
- before the open
- After quarter end
- 37 to 50 days
- 10-Q filed
- 37 to 41 days
- over its last 8
- 10-K filed
- 52 to 69 days
- over its last 7
Based on 8 prior 10-Q filings.
Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR